Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2
Nxera Pharma has announced that partner Neurocrine Biosciences has received IND Acceptance from the FDA a Ph2 of NBI-1117567 in Alzheimer's cognition.
FDA issues novel nods for diabetes monitor, migraine lenses
In a busy week, the FDA granted two De Novo authorisations for consumer health devices and is rumoured to be mulling structural leadership changes.
Expanded US Imaavy approval first ever for wAIHA
The FDA has approved Johnson & Johnson's Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune haemolytic anaemia (wAIHA).
Final judgement favours TwinStrand in Guardant patent case
Court issues final judgement in favour of TwinStrand and the University of Washington in their patent infringement suit against Guardant Health.
Lundbeck taps EVERSANA’s AI Agency for commercialisation
In advance of its NYC event, EVERSANA announces expanded AI agency capabilities and a partnership with brain health giant Lundbeck.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
The MFN effect: what payers expect and how Pharma should res...
A live webinar and audience Q&A with practical insights from global payer research and leading payer experts
The Pharmaceutical Launch Excellence Summit
Where pharma leaders share strategies for successful drug launches.
Inizio Launches Connected Insights to Transform Global Medic...
Expanded APAC expertise, enhanced global infrastructure, and AI-enabled innovation to help life sciences organizations
9th Lab Asset & Facility Management Summit
Enabling Leaner, Smarter & More Resilient R&D Labs
The Evolution Summit Announces September 2026 Program for Cl...
Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.